Company Overview - Lier Chemical Co., Ltd. is located at No. 58, Huasheng Road, Chenghua District, Chengdu, Sichuan Province, established on July 26, 2000, and listed on July 8, 2008. The company primarily engages in the research, production, and sales of efficient, low-toxicity, low-residue safe pesticides, including chloropyridine, organophosphorus, sulfonylurea, and substituted urea [1][2]. Financial Performance - For the period from January to September 2025, Lier Chemical achieved operating revenue of 6.709 billion yuan, representing a year-on-year growth of 29.31%. The net profit attributable to the parent company was 381 million yuan, showing a significant increase of 189.07% year-on-year [2]. - The company has cumulatively distributed 1.496 billion yuan in dividends since its A-share listing, with 720 million yuan distributed over the past three years [3]. Stock Performance - As of November 24, Lier Chemical's stock price decreased by 2.07%, trading at 12.78 yuan per share, with a total market capitalization of 10.230 billion yuan. The stock has increased by 62.39% year-to-date, but has seen a decline of 4.77% over the last five trading days [1]. - The stock's trading volume on November 24 was 154 million yuan, with a turnover rate of 1.48%. The net outflow of main funds was 12.1278 million yuan, with large orders showing a buy of 27.7502 million yuan and a sell of 29.6346 million yuan [1]. Shareholder Structure - As of October 31, the number of shareholders for Lier Chemical was 42,000, a decrease of 2.35% from the previous period. The average circulating shares per person increased by 2.40% to 19,008 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked as the fifth largest with 13.308 million shares, an increase of 5.8814 million shares from the previous period. New shareholder Penghua China 50 Mixed Fund holds 5.256 million shares, while Southern CSI 1000 ETF reduced its holdings by 60,900 shares [3].

Core Viewpoint - Kstar's stock price has experienced fluctuations, with a year-to-date increase of 87.04% but a recent decline of 7.95% over the last five trading days [1] Company Overview - Kstar Technology Co., Ltd. is based in Nanshan District, Shenzhen, Guangdong, and was established on March 17, 1993. It was listed on December 7, 2010. The company specializes in the R&D, production, sales, and services of UPS and valve-regulated sealed lead-acid batteries [1] - The main revenue composition includes smart power and data centers (60.04%), solar storage and charging products and systems (37.16%), supporting products (1.40%), other (0.96%), and new energy revenue (0.44%) [1] Financial Performance - For the period from January to September 2025, Kstar achieved operating revenue of 3.609 billion yuan, representing a year-on-year growth of 23.93%. The net profit attributable to the parent company was 446 million yuan, with a year-on-year increase of 24.93% [2] - Kstar has distributed a total of 1.544 billion yuan in dividends since its A-share listing, with 602 million yuan distributed in the last three years [3] Shareholder Structure - As of September 30, 2025, Kstar had 46,000 shareholders, with an average of 12,285 circulating shares per person. The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 10.6908 million shares, an increase of 2.45 million shares from the previous period [2][3] - New institutional shareholders include Bosera Huixing Return Mixed Fund, holding 5.0283 million shares, and Huatai-PineBridge Technology Innovation Mixed Fund, holding 4.0335 million shares [3]

Core Viewpoint - Lier Chemical's stock has experienced a significant increase of 68.23% year-to-date, with recent trading showing mixed capital flows and a slight decline in share price on November 21 [1][2]. Company Overview - Lier Chemical Co., Ltd. is based in Chengdu, Sichuan Province, and was established on July 26, 2000, with its stock listed on July 8, 2008. The company specializes in the research, production, and sales of safe pesticides, including chlorinated pyridine, organophosphorus, sulfonylurea, and substituted urea [1]. - The revenue composition of Lier Chemical includes: 61.17% from pesticide raw materials, 21.31% from pesticide formulations, 9.09% from pesticide intermediates, 4.29% from agrochemical product circulation, 3.45% from chemical materials, 0.56% from environmental disposal, and 0.14% from other sources [1]. Financial Performance - For the period from January to September 2025, Lier Chemical achieved a revenue of 6.709 billion yuan, representing a year-on-year growth of 29.31%. The net profit attributable to shareholders was 381 million yuan, showing a remarkable increase of 189.07% compared to the previous year [2]. - Since its A-share listing, Lier Chemical has distributed a total of 1.496 billion yuan in dividends, with 720 million yuan distributed over the past three years [3]. Shareholder Structure - As of October 31, 2025, Lier Chemical had 42,000 shareholders, a decrease of 2.35% from the previous period. The average number of circulating shares per person increased by 2.40% to 19,008 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 13.308 million shares, an increase of 5.8814 million shares from the previous period. New shareholder Penghua China 50 Mixed Fund holds 5.256 million shares [3].

Core Viewpoint - The stock of Rabbit Baby (兔宝宝) has shown a mixed performance in recent trading, with a year-to-date increase of 21.37% but a slight decline in the last five trading days [1][2]. Group 1: Stock Performance - As of November 20, Rabbit Baby's stock price increased by 2.01%, reaching 13.70 CNY per share, with a total market capitalization of 11.368 billion CNY [1]. - The stock has experienced a net outflow of 178,800 CNY in main funds, with large orders buying 3.0254 million CNY (7.00%) and selling 3.2042 million CNY (7.42%) [1]. - The stock has fluctuated with a 10.13% increase over the last 20 days and a 33.61% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Rabbit Baby reported a revenue of 6.319 billion CNY, a year-on-year decrease of 2.25%, while the net profit attributable to shareholders increased by 30.44% to 629 million CNY [2]. - The company has distributed a total of 2.942 billion CNY in dividends since its A-share listing, with 1.6 billion CNY distributed in the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Rabbit Baby decreased by 20.59% to 34,300, while the average circulating shares per person increased by 25.94% to 21,454 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 7th place with 7.6104 million shares, an increase of 1.2541 million shares from the previous period [3].

Core Viewpoint - The stock of Kai Run Co., Ltd. has experienced fluctuations, with a recent decline of 2.04% and a year-to-date increase of 0.18%, indicating mixed performance in the market [1] Financial Performance - For the period from January to September 2025, Kai Run Co., Ltd. achieved a revenue of 3.719 billion yuan, representing a year-on-year growth of 22.94%. However, the net profit attributable to shareholders decreased by 13.38% to 278 million yuan [2] - The company has distributed a total of 353 million yuan in dividends since its A-share listing, with 161 million yuan distributed over the past three years [3] Shareholder Information - As of November 10, 2025, the number of shareholders for Kai Run Co., Ltd. was 7,495, a decrease of 2.90% from the previous period. The average circulating shares per person increased by 2.99% to 18,641 shares [2] - The top ten circulating shareholders include notable funds such as E Fund New Economy Mixed Fund and E Fund Kexiang Mixed Fund, with some shareholders reducing their holdings while new shareholders have entered [3] Market Activity - The stock has seen a trading volume of 13.69 million yuan with a turnover rate of 0.39%, and the total market capitalization stands at 5.887 billion yuan [1] - The stock has appeared on the "Dragon and Tiger List" once this year, with a net buy of -13.2465 million yuan on the last occasion [1]

Core Viewpoint - Hualu Hengsheng's stock price has shown a significant increase of 33.71% year-to-date, despite a recent decline of 1.74% over the past five trading days, indicating volatility in the market [1][2]. Financial Performance - For the period from January to September 2025, Hualu Hengsheng reported a revenue of 23.55 billion yuan, a year-on-year decrease of 6.46%, and a net profit attributable to shareholders of 2.37 billion yuan, down 22.14% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 8.97 billion yuan, with 4.78 billion yuan distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 16.59% to 44,000, while the average number of circulating shares per person increased by 19.90% to 48,213 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 37.98 million shares, and Huatai-PB CSI 300 ETF, holding 25.20 million shares, both showing a decrease in holdings compared to the previous period [3]. Market Activity - On November 19, Hualu Hengsheng's stock price rose by 2.03% to 28.16 yuan per share, with a trading volume of 406 million yuan and a turnover rate of 0.69% [1]. - The company's total market capitalization stands at 59.79 billion yuan [1]. Business Overview - Hualu Hengsheng, established on April 26, 2000, and listed on June 20, 2002, is primarily engaged in the production and sale of urea and methanol [1]. - The revenue composition includes 48.34% from new energy and new materials, 24.61% from chemical fertilizers, 10.82% from acetic acid and derivatives, and other segments [1]. Industry Classification - Hualu Hengsheng is classified under the Shenwan industry as basic chemicals - agricultural chemical products - nitrogen fertilizers, and is associated with sectors such as fertilizers and coal chemical [1].

Core Viewpoint - Yun Aluminum Co., Ltd. has shown significant stock performance with an 85.57% increase year-to-date, despite a recent decline of 7.00% over the last five trading days [1] Group 1: Stock Performance - As of November 19, Yun Aluminum's stock price reached 24.18 CNY per share, with a market capitalization of 838.55 billion CNY [1] - The stock has experienced a trading volume of 4.83 billion CNY, with a turnover rate of 0.58% [1] - Year-to-date, the stock has increased by 85.57%, while it has decreased by 7.00% in the last five trading days, increased by 10.61% in the last 20 days, and increased by 43.08% in the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Yun Aluminum reported a revenue of 440.72 billion CNY, representing a year-on-year growth of 12.47% [2] - The net profit attributable to shareholders for the same period was 43.98 billion CNY, reflecting a year-on-year increase of 15.14% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Yun Aluminum was 79,100, a decrease of 8.51% from the previous period [2] - The average number of circulating shares per shareholder increased by 9.30% to 43,857 shares [2] - The company has distributed a total of 60.69 billion CNY in dividends since its A-share listing, with 38.84 billion CNY distributed in the last three years [3]

Core Viewpoint - Tiger Med's stock price has experienced a decline of 3.17% year-to-date, with a significant drop of 21.49% over the past 60 days, indicating potential challenges in the market [1] Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1] - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1] - The revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1] Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%. However, the net profit attributable to the parent company was 1.020 billion yuan, reflecting a year-on-year increase of 25.45% [2] - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Tiger Med was 48,400, a decrease of 6.01% from the previous period. The average circulating shares per person remained at 0 shares [2] - The top circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares, and China Europe Medical Health Mixed A, which increased its holdings by 1.218 million shares [3]

Core Viewpoint - The stock price of XW Communication has experienced fluctuations, with a recent decline of 2.03% on November 18, 2023, despite a year-to-date increase of 19.88% [1][2]. Group 1: Stock Performance - As of November 18, 2023, XW Communication's stock price is reported at 30.44 CNY per share, with a trading volume of 6.08 billion CNY and a turnover rate of 2.41%, resulting in a total market capitalization of 294.53 billion CNY [1]. - Year-to-date, the stock has increased by 19.88%, but it has seen a decline of 7.03% over the last five trading days [2]. - The stock has shown a 4.28% increase over the last 20 days and a 16.99% increase over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, XW Communication reported a revenue of 6.462 billion CNY, reflecting a year-on-year growth of 1.07%. However, the net profit attributable to shareholders decreased by 8.77% to 486 million CNY [2]. - The company has distributed a total of 5.98 billion CNY in dividends since its A-share listing, with 1.93 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for XW Communication is 89,800, which is a decrease of 0.78% from the previous period. The average number of tradable shares per shareholder has increased by 0.56% to 9,159 shares [2]. - The top ten circulating shareholders include notable ETFs, with the E Fund Growth Enterprise Board ETF holding 17.2028 million shares, a decrease of 2.8866 million shares from the previous period [3].

Core Viewpoint - Zhongman Petroleum's stock has shown significant growth this year, with a 30.41% increase year-to-date and a notable rise in recent trading days, indicating strong market interest and potential investment opportunities [1][2]. Company Overview - Zhongman Petroleum and Natural Gas Group Co., Ltd. is located in Shanghai and was established on June 13, 2003, with its listing date on November 17, 2017. The company specializes in exploration and development, oilfield engineering, and petroleum equipment manufacturing [1]. - The main revenue sources for Zhongman Petroleum are crude oil and its derivatives (54.70%), drilling engineering services (38.43%), and sales and leasing of drilling rigs and accessories (5.97%) [1]. Financial Performance - For the period from January to September 2025, Zhongman Petroleum reported a revenue of 2.985 billion yuan, a year-on-year decrease of 2.18%, and a net profit attributable to shareholders of 453 million yuan, down 32.18% year-on-year [2]. - The company has distributed a total of 979 million yuan in dividends since its A-share listing, with 771 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Zhongman Petroleum had 30,100 shareholders, a decrease of 32.03% from the previous period, with an average of 15,360 circulating shares per shareholder, an increase of 47.13% [2]. - Notable changes in institutional holdings include an increase in shares held by major funds, with Dazhong New Industry Mixed A becoming the third-largest shareholder, increasing its holdings by 4.4124 million shares [3].